Post by
Ferrel on Feb 07, 2014 10:17pm
regarding innexus dynamic cross linking technology
you guys are using.
can you inbox me please, i have a boat load of shares in that stock and would like to have any information you can give me.
ixs.h and ixsbf on pinks.
since our ceo died in a plane crash back in 2010 our company went blackout.
we have numerous collaborators ,and i finally found you guys through one of your patents
using our technology.
anything you can offer i will pass over to the shareholders of ixs.h bullboard as we have not seen any news in years and have no idea what is going on.
thank you very very much in advance.
(I a 2nd-generation humanized anti-CD20 antibody of Immunomedics or DXL625,mmunomedics) which are comprised of a divalent anti-CD20 IgG of veltuzumab and a pair of stabilized dimers of Fab derived from milatuzumab, an anti-CD20 mAb enhanced with InNexus' Dynamic Cross Linking technology, of Inexus Biotechnology both are humanized anti-CD20 antibodies are suitable.